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Most patients with interstitial lung disease (ILD) associated with collagen vascular diseases
(CVD) have a chronic indolent course with a relatively favorable prognosis; however, acute
progression has been reported in some polymyositis-dermatomyositis patients. This study
evaluated the prevalence, clinical features, and outcome relative to the presentation type
of ILD in polymyositis-dermatomyositis (PM–DM).
Ninety-nine patients with newly diagnosed polymyositis-dermatomyositis seen at the
Asan Medical Center in Korea between January 1990 and December 2004 were
enrolled. The clinical, radiological, and pathological findings were retrospectively
reviewed. ILD were divided into acute (dyspnea within 1 month before diagnosis) or
chronic types.
ILD was found on chest radiographs in 33 patients (33.3%), and 11 (33.3%) of these were
considered acute. The acute group presented with more severe respiratory symptoms,
hypoxemia, and poorer lung function. Patients with an acute presentation had ground glass
opacity and consolidation on high-resolution computed tomography (HRCT), in contrast to
reticulation and honeycombing in the chronic type. Surgical lung biopsy of one acute-type
patient revealed diffuse alveolar damage, whereas biopsies in the chronic type showed
usual interstitial pneumonia (UIP) in four cases and nonspecific interstitial pneumonia
(NSIP) in another four. Eight acute-type patients (72.7%) died of respiratory failure within
1–2 months despite steroid therapy. The 3-year mortality rate of the chronic-type patientsElsevier Ltd. All rights reserved.
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(10.2%).
In polymyositis-dermatomyositis, the acute, severe form of ILD was not infrequent.
& 2007 Elsevier Ltd. All rights reserved.Table 1 Definition for interstitial lung disease (ILD).
Interstitial lung disease associated with PM–DM
(1) Symptoms/signs: dry cough, exertional dyspnea, and
crackles at both lung bases
(2) Chest radiograph or HRCT (bilateral reticular/
reticulonodular infiltration, ground glass opacity,
airspace consolidation, or honeycombing)
(3) PFT: restrictive defect or low diffusion capacity
(4) No evidence of known causes, such as infection, heart
failure, and drug reaction
(5) Surgical lung biopsiesIntroduction
Interstitial lung disease (ILD) is frequent in collagen vascular
diseases (CVD) such as scleroderma, Sjo¨gren’s syndrome,
systemic lupus erythematosus, rheumatoid arthritis, and
polymyositis-dermatomyositis (PM–DM).1–7 Although the
clinical features of ILD associated with CVD are similar to
those of idiopathic interstitial pneumonia (IIP), the survival
in CVD-ILD is much better, and most patients have a chronic
indolent course.8–11 Nevertheless, there is a subset of
patients with PM–DM who have rapidly progressive respira-
tory failure, and this subset has high mortality compared
with the overall survival of PM–DM-ILD.12–14 Consequently,
the survival curve of PM–DM shows an initial rapid drop in
the first year after diagnosis, representing the accelerated
mortality of this subset, and a slower decline thereafter.15,16
A review of surgical lung biopsy specimens in cases of ILD
associated with scleroderma and Sjo¨gren’s syndrome has
revealed that the nonspecific interstitial pneumonia (NSIP)
pattern is more common than ‘‘usual interstitial pneumo-
nia’’ (UIP).2,5,17,18 Similarly, in PM–DM, Douglas et al.19,20
and Cottin et al.19,20 reported that NSIP was the most
common pattern. However, in Douglas et al.19,20 surgical
lung biopsies were reviewed in only 31% of the patients.
Therefore, the reported surgical lung biopsy results might
not provide the entire picture for PM–DM-ILD. At our
institution, almost all patients with PM–DM admitted for a
diagnostic work-up routinely have a chest radiograph, so it is
relatively easy to check for the presence of ILD. This study
reviews the overall clinical features of a relatively large
series of patients with PM–DM, focusing on the relative
prevalence of ILD in this group, to determine the clinical and
radiological findings of the acute type of ILD.
Patients and methods
Study population
This retrospective study was performed at Asan Medical
Center, a 2000 bed, university affiliated, tertiary referral
center in Seoul, Korea. From January 1990 to December
2004, 107 patients were newly diagnosed with PM–DM based
on Bohan and Peter’s criteria: symmetric proximal muscle
weakness, with or without dysphasia or respiratory muscle
weakness; muscle enzyme elevation; electromyographic
abnormalities; compatible muscle biopsy; and skin rash of
dermatomyositis.21,22 Eight patients with overlap syndrome
combined with other CVDs were excluded, and thus 99
patients were included in the study. All the patients had a
chest radiograph taken at the time of diagnosis, and
interstitial pneumonia was found in 33 patients (Table 1).
The interstitial pneumonia was divided into two groups
according to the respiratory symptoms. The acute type of
ILD (acute ILD) was defined as the development of rapidlyprogressive severe dyspnea and hypoxemia requiring oxygen
therapy or ventilator care within one month preceding
diagnosis,23–27 and the others were classified as the chronic
type (chronic ILD).Clinical and laboratory findings
Clinical data and laboratory results were extracted from the
patients’ medical records. The factors examined included
clinical history, physical examination, laboratory tests,
pulmonary function tests, radiological findings, bronchoal-
veolar lavage (BAL) fluid findings, and biopsy results.Chest radiographs and computed tomography (CT)
of the chest
Chest radiographs and high-resolution computed tomogra-
phy (HRCT) examinations of the lungs were reviewed and
interpreted by a single-chest radiologist blinded to the
biopsy results and clinical outcomes. Radiological evidence
of ILD on chest X-ray includes ground glass opacity, patchy
bilateral consolidation, and basal-predominant reticular
opacities. HRCTwas performed for the differential diagnosis
of ILD in patients with respiratory symptoms or abnormal
chest radiographs. Five patients with respiratory symptoms
and normal chest radiographs underwent HRCT. Two of them
had a normal HRCT, and the remaining three proved to have
an infection. Another 16 patients with abnormal chest
radiographs were excluded because of heart failure (n ¼ 5),
infection (n ¼ 9), carcinoid tumor, or amyloidosis with
bilateral radiological infiltration. The radiologist (J.B.S.)
determined the presence, degree, and extent of consolida-
tion, ground glass opacity (GGO), traction bronchiectasis,
reticulation, and honeycombing on HRCT.28
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Spirometry was performed with a Sensor Medics 2100 (Yorba
Linda, CA, USA), the diffusion capacity of the lung for
carbon monoxide (DLCO) was measured with a Sensor Medics
Model Vmax 22, and total lung capacity (TLC) was measured
using a Sensor Medics Auto Box 6200. All results are
expressed as a percentage of normal predicted values,29
and values below 80% of normal were considered abnormal.
Improvement or worsening was defined as a change greater
than 10% of the forced vital capacity (FVC) or TLC (more
than 15% in DLCO) in either direction.
30
Surgical lung biopsy
A surgical lung biopsy was performed to confirm the pattern
of interstitial pneumonia. Given the patients’ general
condition, a surgical lung biopsy was performed in nine
patients only. Two lung pathologists (M.K. and T.V.C.)
reviewed the lung biopsy slides independently, and the
histology of each lung was classified according to the
patterns defined in the new ATS/European Respiratory
Society consensus classification for IIPs.31
Statistical analysis
The data are presented as the mean7SD for continuous
variables and as percentages for categorical variables.
Statistical analyses were performed using SPSS for Windows
version 11.0 (Chicago, IL). Continuous variables were
compared using the Mann–Whitney U test or the Kruskal–
Wallis test, whereas categorical variables were compared
using the chi-square test or Fisher’s exact test. Cumulative
survival probabilities were estimated using the Kaplan–
Meier method. The log-rank test was used to compare the
survival of groups of patients. A p valueo0.05 was defined
as statistically significant (all tests were two tailed).
Results
Prevalence of ILD by chest radiography
ILD was diagnosed in 33 of the 99 patients (33.3%) by chest
X-ray. Of the 33 patients with ILD, 11 (33.3%) were acute,
and 22 (66.7%) were chronic type. ILD and PM–DM were
diagnosed simultaneously in 22 of the 33 patients (66.7%),
and ILD was diagnosed before PM–DM in six patients (18.2%).
Clinical features and laboratory findings at the time
of diagnosis
The patient demographics, symptoms, laboratory tests, and
BAL fluid findings recorded at initial presentation are
summarized in Table 2. The PM–DM patients were divided
into three groups, depending on the presence and type of
ILD. Inflammatory markers such as the erythrocyte sedi-
mentation rate (ESR) and serum albumin level differed
among the three groups (po0.05); there were no significant
differences in the demographic features or muscle enzymes.
Antinuclear antibody (ANA) had a higher prevalence in thePM–DM patients without ILD. A positive ANA reaction might
be a good prognostic marker (odds ratio 0.258, 95%
confidence interval 0.060–1.105, p ¼ 0.068). Jo-1 antibody
had a higher prevalence in the chronic ILD group. In the
patients with acute ILD, the respiratory symptoms were not
only more severe but were also the main reason for
admission in the majority (73%) of the patients. By contrast,
most of the patients with chronic ILD had only minimal
respiratory symptoms, and about one-third were asympto-
matic. Of those without ILD, 14 patients complained of
dyspnea, and further work-up, such as 2-D echocardiogra-
phy, exercise PFTs, measured maximal inspiratory pressure,
HRCT, and lung biopsy, revealed the causes of the dyspnea to
be heart failure (n ¼ 5), combined pneumonia (n ¼ 4),
muscle weakness (n ¼ 3), cystic bronchiectasis (n ¼ 1),
and amyloidosis (n ¼ 1). The BAL fluid in the chronic ILD
cases showed lymphocytosis, in contrast to the elevated
percentage of neutrophils in the acute-type cases, although
the difference was not statistically significant due to the
small number of patients who underwent BAL.
PFTs
PFTs were performed in 28 of the 33 patients with ILD and in
18 of the 66 patients without ILD (Table 3). Five patients
(45.5%) with acute ILD could not complete the PFTs because
of severe dyspnea and hypoxemia. The lung function of the
remaining six patients with acute ILD was still the lowest as
compared with the other groups. Among the patients with
ILD, a restrictive defect (92.9%) was the most common lung
function abnormality, followed by a low DLCO (88.0%), and
80% of the patients had a restrictive defect with a low DLCO.
Among the patients without ILD, three had a mildly
restrictive defect attributable to respiratory muscle weak-
ness, and another four patients had a restrictive pattern
with a low DLCO attributable to concomitant diseases, such
as heart failure (n ¼ 2), pneumonia (n ¼ 1), and bronchiec-
tasis (n ¼ 1).
HRCT of the chest
HRCT was performed in 31 of the 33 patients in the ILD
group. The major findings are summarized in Table 4. In
acute ILD, all the patients had consolidation (n ¼ 8) and
GGO (n ¼ 2), whereas in chronic ILD, reticular densities with
(n ¼ 3) or without honeycombing predominated (Fig. 1). The
most common distribution of the abnormalities on HRCTwas
basal and subpleural in both groups. Five patients with acute
ILD had a predominantly peribronchial distribution.
Surgical lung biopsies
Surgical lung biopsies were performed in nine patients only
(eight chronic and one acute ILD). Many patients with acute
ILD were too ill to undergo a surgical lung biopsy and started
treatment with high-dose steroids shortly after admission.
The pathologic findings in the nine biopsied cases were an
organizing diffuse alveolar damage (DAD) pattern in the
single acute ILD case and NSIP (4 cases) and UIP (4 cases) in
the chronic ILD cases.
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Table 2 Summary of the initial clinico-laboratory data for the patients with polymyositis-dermatomyositis.
Without ILD With ILD p Valuey
Acute type Chronic type
Number of patients 66 11 22
Male/female, Number 29/37 4/7 10/12 NS
Age, years 47.2716.0 47.974.1 48.972.7 NS
Smoking history, Number
Never/former/current 44/6/13 9/0/1 12/1/8 NS
Symptoms and signs at the time of admission, %
Dyspnea as a chief complaint 81.8 31.8 0.004
Cough 9.1 100.0 45.5 0.000
Dyspnea 21.2 81.8 59.1 0.000
Fever 25.8 45.5 45.5 NS
Laboratory tests
PF ratio mm Hg 2317147 385782 0.004
ESR, mm/h 35.9730.9 56.2729.3 53.1725.9 0.027
LDH, IU/L 13247999 260472511 16137253 NS
CK, IU/L 378776111 105471954 301273199 NS
Aldolase, SU/mL 16.5717.1 18.4716.8 24.3725.1 NS
Albumin, g/dL 3.470.1 2.970.1 2.970.2 0.000
Antinuclear antibodies (ANA) 22/66 0/11 4/22 0.010
Positive/negative, no. (%) (33.3%) (0%) (18.2%)
Anti-Jo-1 Positive/negative, No. 1/38 1/8 3/13 0.040
Initial BAL finding
Macrophages, % 55.8735.0 36.9727.1 NS
Lymphocytes, % 12.1710.6 47.4721.9 0.032
Neutrophils, % 29.1741.0 13.9710.6 NS
Eosinophils, % 2.974.5 1.673.0 NS
PF ratio: PaO2/FiO2 ratio.
Data are presented as the mean7SD unless indicated otherwise.
yExact test for categorical variables and Mann–Whitney U test or Kruskal–Wallis test for continuous variables.
Table 3 Results of the initial pulmonary function tests



























Data are presented as the mean7SD.
yTLC data of patients without ILD were not available.
Table 4 Initial high-resolution computed tomography
and histopathological findings.
Acute ILD Chronic ILD
Major pattern in the initial HRCT
Number of patients 10 21
Consolidation 8 1








J. Won Huh et al.1764Clinical course of ILD
Acute type of ILD
Eight of the 11 patients (72.7%) with acute ILD died of
rapidly progressing respiratory failure within 1–2 months
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Figure 1 Radiological findings of the patients with acute and chronic interstitial lung disease. (A) Acute ILD. (a) The chest X-ray
taken at the initial presentation shows slightly increased interstitial densities in both lower lung fields, and (b) HRCT shows a
subpleural distribution of GGO with focal consolidation. (c) The chest X-ray taken 2 weeks later shows increased opacities throughout
the entire lung fields with an endotracheal tube. (B) Chronic ILD. (a) The chest X-ray taken at the initial presentation shows slightly
increased interstitial densities in both lower lung fields, and (b) HR-CT shows a subpleural distribution of reticular densities with
traction bronchiectasis. (c) The chest X-ray taken 5 months later shows no significant change compared with the initial chest X-ray.
Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis 1765despite all therapeutic endeavors, including steroid
pulse therapy and immunosuppressant therapy. Non-survi-
vors had a lower oxygen tension than survivors, but
there were no differences in the demographic, clinical, or
laboratory findings between the survivors and non-survivors
(Table 5). Although the numbers were too small for
statistical comparison, the extent at HRCT seemed
to be more widespread in the non-survivors. Three
survivors had a patchier peribronchial distribution, suggest-
ing a bronchiolitis obliterans organizing pneumonia
(BOOP) pattern. Three survivors were stable or partially
improved clinically after 3, 5, and 9 years, res-
pectively.Chronic type of ILD
All 22 patients were treated with prednisolone either alone
(22.7%) or in combination with immunosuppressants (77.3%).Six months after the diagnosis, lung function had improved
in the survivors compared with the initial values (FVC:
67.7720.2 vs. 60.7713.7% predicted, p ¼ 0.034; DLCO:
63.7719.2 vs. 58.9716.5% predicted, p ¼ 0.093). On long
term follow-up, PFTs revealed the maintenance of the
improved state for up to 3 years (Fig. 2). In terms of
myositis, 11 patients (50%) exhibited complete remission,
and eight (36.3%) showed partial improvement in muscle
strength.Survival
As a whole, the patients with ILD had significantly lower
survival rates than those without ILD. The 3-year survival
rate of the patients with ILD was 61.6% and that of the
patients without ILD was 89.8% (po0.05, Fig. 3). Subgroup
analysis of the patients with ILD showed that the 3-year
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Table 5 Comparison of survivors and non-survivors in acute interstitial lung disease.
Non-survivor Survivor P value
Number of patients 8 3
Male/female gender, Number 4/4 0/3 0.068
Age, years 47.6715.2 48.7710.1 0.776
PF ratio, mm Hg 187776 3487245 0.376
PaCO2, mm Hg 31.678.6 36.573.9 0.376
WBC, /mm3 770074300 1210079000 0.376
ESR, mm/h 59.9733.4 47.7719.4 0.667
CK, IU/L 142473026 206172950 0.921
Aldolase, SU/mL 22.1740.0 32.0718.8 0.250
Major Pattern on HRCT, Number
Consolidation 5 3 0.467
Ground glass opacity 2
Surgical lung biopsy DAD(1)
Data are presented as the mean7SD, unless indicated otherwise.
Figure 2 Changes in pulmonary function of the patients with chronic type of interstitial lung disease*. *The data are presented as
the mean7SD. po0.05 compared with initial pulmonary functions.
J. Won Huh et al.1766survival rate was 27.3% for the acute form and 78.8% for the
chronic form (po0.05). The survival rate of the chronic ILD
group was not significantly different from that of the
patients without ILD.Both the survival rate and the cause of death differed
between the two ILD groups. Eight patients died of
progressive ILD in the acute ILD group, whereas the causes
of death in the chronic-ILD group were sepsis with multi-
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Figure 3 Overall survival curves of the patients with poly-
myositis-dermatomyositis (PM–DM) according to the state of
lung involvement (po0.05).
Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis 1767organ failure (n ¼ 3), superimposed pneumonia (n ¼ 1), and
cancer progression (n ¼ 1).
The causes of death in the PM–DM patients without ILD
included sepsis (n ¼ 4), cancer progression (n ¼ 3), super-
imposed pneumonia (n ¼ 1), and heart failure (n ¼ 1).Discussion
Here, we have shown that the clinical type of ILD associated
with PM–DM differs from the chronic course of other CVD-
ILDs.6,8 One-third of the patients with ILD associated with
PM–DM had the acute severe form, with rapidly progressive
respiratory failure and high mortality. An acute form of ILD is
encountered in other CVDs, but it is relatively rare.32,33 As
almost all newly diagnosed PM–DM patients at our institution
were admitted for a diagnostic work-up, we believe that our
estimation of the prevalence of ILD in this group of patients
approach to the true prevalence. Furthermore, detailed
histories with laboratory and radiological findings were
available, providing overall clinical pictures of ILD in
PM–DM.
Most CVDs present with a variety of pleuropulmonary
manifestations, with ILD being one of the most common. The
reported prevalence of ILD in CVDs varies not only with the
nature of the CVD but also the method of detection.6,34–36
The prevalence of ILD in PM–DM patients has been reported
to be in the range of 5–46%, depending on the method used.
In most studies, the presence of ILD affected the treatment
and outcome of PM–DM.23,37,38 In our study, one-third of the
patients had ILD on chest X-ray at presentation; this might
actually be an underestimation of the true prevalence
because of the relative insensitivity of chest radiography.
However, we think that this includes all the patients with
clinically significant disease, given that 24% of the patients
with radiological ILD were still asymptomatic and that
further work-up of other patients complaining of respiratory
symptoms failed to reveal more patients with ILD.
Many reports have suggested that the prognosis of CVD-
ILD is much better than that of IIP, despite their clinical andradiological similarities.8–11 The ATS/ERS Consensus Classi-
fication of IIPs subclassifies IIPs into seven different types,
and many studies have reported that idiopathic NSIP has a
better prognosis than IPF/UIP.39–46 A recent review of
surgical lung biopsy specimens of CVD-ILD revealed that
the NSIP pattern was predominant in most CVDs, such as
scleroderma, PM–DM, and Sjo¨gren’s syndrome.2,5,17–20 In
contrast, the UIP pattern is predominant in IIP.47 It is
uncertain whether the better survival in CVD-ILD is
attributable mainly to the relative frequency of NSIP with
its more favorable prognosis or whether there is a genuine
biological difference between IIP and CVD-ILD. Similar to the
diversity of CVDs, the forms of ILD in the various CVDs differ
considerably in their frequency. For example, in scleroder-
ma, most reports agreed that the NSIP pattern is predomi-
nant.17,18 However, in Sjo¨gren’s syndrome, although the
NSIP pattern is the most frequent, many different kinds of
ILD have been reported, including UIP, LIP, amyloidosis, and
even lymphoma.2,28,48 In rheumatoid arthritis, not only
different types of interstitial pneumonia but also small
airway diseases are not infrequent, and UIP is reported to be
more common than the NSIP pattern.3,49 Regardless of the
histological pattern, most cases of CVD-ILD seem to follow a
relatively chronic indolent course,6–8 and there are only
isolated case reports of acute forms of ILD in CVD other than
PM–DM.32,33 By contrast, there are many reports of acute ILD
in PM–DM, although the relative prevalence or detailed
clinical comparisons (versus chronic disease) are lack-
ing.12,13,50–52 The reports that showed the predominance
of the NSIP pattern in PM–DM may result from selection bias
because surgical lung biopsies tend to be performed in
relatively stable patients.19,20
Thus, we studied the relative prevalence and clinical
characteristics of the subtypes of ILD in PM–DM and
confirmed that ILD in PM–DM can be divided into two clinical
types with different radiological and pathological findings
and different outcomes. Furthermore, our results revealed
that acute ILD is not infrequent (33% of the ILD associated
PM–DM). Many patients are too ill to tolerate either surgical
lung biopsies or pulmonary function tests. Most of them
were admitted for respiratory symptoms with severe
hypoxemia, rather than muscle problems, suggesting that
clinicians should be alert to the possibility of PM–DM in this
situation. Most died of rapidly progressing respiratory failure
within 1–2 months, despite high-dose steroid therapy and
ventilator care. Only one patient had a surgical lung biopsy,
which revealed a DAD pattern similar to other reports.12–14 A
BOOP pattern may also have a clinical presentation similar
to a DAD pattern, as reported in PM–DM.13,53 Unfortunately,
we cannot confirm the relative prevalence of the BOOP and
DAD patterns in PM–DM. Patients with the BOOP pattern
have been reported to have a better prognosis than those
with UIP or DAD patterns, not only in IIP but also in CVD-
ILD.13,33,40,41 The three patients with the acute-type ILD
who survived in our series had HRCT features more
suggestive of BOOP, i.e. bilateral multifocal consolidation
in the bronchial distribution, but the diagnoses could not be
confirmed histologically.
The chronic form of ILD in PM–DM, which is more common
than the acute type, presented with slowly progressive
dyspnea and cough, with many cases being asymptomatic.
HRCT revealed reticular densities with or without
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some of them. Three patients had honeycombing on the
HRCT at the time of the diagnosis of PMDM, had developed
respiratory symptoms 6–24 months prior to the diagnosis of
PM–DM. It has been well known that in some patients, the
ILD can precede the manifestation of CVD for several years
and long standing ILD represented by honeycombing was
reported in other studies.6,7,19,54–58
Owing to the small number of the surgical lung biopsies,
we could not confirm the predominance of the NSIP pattern
in chronic-type ILD in PM–DM. The course of chronic ILD was
stable or improved with treatment in most patients on long
term follow-up. Survival analysis showed that these patients
with chronic ILD had a survival rate similar to that of the
patients without ILD.
The reported characteristics of acute ILD include the
lesser complaints of muscle weakness, a lack of elevation of
serum creatine phosphokinase, and negative tests for
autoantibodies (anti-Jo-1 antibodies).59,60 However, we
could not confirm all of these findings. The higher ESR and
lower albumin level in our patients with ILD suggest that
patients with ILD have more severe systemic inflammation
than those without ILD.
The mortality of PM–DM patients has declined with early
diagnosis and improved treatment modalities.61,62 Many
deaths in these patients result from respiratory failure,
including those who develop progressive ILD and pneumonia
or sepsis. A shorter disease history, rash, dysphagia, fever,
older age, and leukocytosis have been associated with
reduced survival.15 In our study, acute ILD had a high
mortality rate, requiring more aggressive treatment with a
combination of high dose steroids, immunosuppressive
agents, and newer modalities, as in other reports.50,63 This
study has several potential limitations. First, the frequency
of ILD might be underestimated due to the comparatively
low sensitivity of chest radiography. Second, a pathologic
diagnosis of ILD was made in only a few patients. Third, the
prevalence of acute ILD might have been overestimated, as
our clinic is a university-affiliated, tertiary referral center.
As a conclusion, we showed that the acute severe form of
ILD is not infrequent (33% of the ILD associated PM–DM),
unlike the predominance of the chronic form of ILD observed
in other CVDs. This acute type presented with respiratory
symptoms rather than muscle problems, and HRCT might be
useful for predicting the prognosis.
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